Metabolic syndrome is associated with severe fibrosis in chronic viral hepatitis and non-alcoholic steatohepatitis

Alimentary Pharmacology and Therapeutics

Volumn 27, Issue 1, 2008, Pages 80-89

  Tsochatzis, E ^a   Papatheodoridis, G V ^a   Manesis, E K ^a   Kafiri, G ^b   Tiniakos, D G ^a   Archimandritis, A J ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b HIPPOKRATION HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTATE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE;

ADULT; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHRONIC HEPATITIS; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEPATITIS B; HEPATITIS C; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INDEPENDENT VARIABLE; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER NECROSIS; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NON ALCOHOLIC STEATOHEPATITIS; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY;

ADULT; AGE FACTORS; AGED; ALANINE TRANSAMINASE; FATTY LIVER; FEMALE; GAMMA-GLUTAMYLTRANSFERASE; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PREVALENCE; PROSPECTIVE STUDIES;

EID: 36749090655     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2007.03538.x     Document Type: Article

References (30)

1. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005 365: 1415 28.
2. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP). Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001 285: 2486 97.
3. Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001 24: 683 9.
4. Marchesini G, Brizi M, Bianchi G, et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001 50: 1844 50.
5. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006 43: S99 112.
6. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999 116: 1413 9.
7. Lonardo A, Lombardini S, Ricchi M, Scaglioni F, Loria P. Review article: hepatic steatosis and insulin resistance. Aliment Pharmacol Ther 2005 22 (Suppl. 2 64 70.
8. Machado M, Cortez-Pinto H. Non-alcoholic steatohepatitis and metabolic syndrome. Curr Opin Clin Nutr Metab Care 2006 9: 637 42.
9. Powell EE, Jonsson JR, Clouston AD. Steatosis: co-factor in other liver diseases. Hepatology 2005 42: 5 13.
10. Rubbia-Brandt L, Fabris P, Paganin S, et al. Steatosis affects chronic hepatitis C progression in a genotype specific way. Gut 2004 53: 406 12.
11. Tsochatzis E, Papatheodoridis GV, Manesis EK, et al. Hepatic steatosis in genotype 4 chronic hepatitis C is mainly because of metabolic factors. Am J Gastroenterol 2007 102: 634 41.
12. Poynard T, Ratziu V, McHutchison J, et al. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 2003 38: 75 85.
13. Tsochatzis E, Papatheodoridis GV, Manesis EK, Chrysanthos N, Kafiri G, Archimandritis AJ. Hepatic steatosis in chronic hepatitis B develops due to host metabolic factors: a comparative approach with genotype 1 chronic hepatitis C. Dig Liver Dis 2007 39: 936 42.
14. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985 28: 412 9.
15. Ikeda Y, Suehiro T, Nakamura T, Kumon Y, Hashimoto K. Clinical significance of the insulin resistance index as assessed by homeostasis model assessment. Endocr J 2001 48: 81 6.
16. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995 22: 696 9.
17. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999 94: 2467 74.
18. Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003 37: 917 23.
19. Kang H, Greenson JK, Omo JT, et al. Metabolic syndrome is associated with greater histologic severity, higher carbohydrate, and lower fat diet in patients with NAFLD. Am J Gastroenterol 2006 101: 2247 53.
20. Shaheen M, Echeverry D, Oblad MG, Montoya MI, Teklehaimanot S, Akhtar AJ. Hepatitis C, metabolic syndrome, and inflammatory markers: Results from the Third National Health and Nutrition Examination Survey [NHANES III]. Diabetes Res Clin Pract 2007 75: 320 6.
21. Athyros VG, Bouloukos VI, Pehlivanidis AN, et al. The prevalence of the metabolic syndrome in Greece: the MetS-Greece Multicentre Study. Diabetes Obes Metab 2005 7: 397 405.
22. Thanopoulou A, Karamanos B, Angelico F, et al. Epidemiological evidence for the non-random clustering of the components of the metabolic syndrome: multicentre study of the Mediterranean Group for the Study of Diabetes. Eur J Clin Nutr 2006 60: 1376 83.
23. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002 287: 356 9.
24. Siagris D, Christofidou M, Theocharis GJ, et al. Serum lipid pattern in chronic hepatitis C: histological and virological correlations. J Viral Hepat 2006 13: 56 61.
25. Serfaty L, Andreani T, Giral P, Carbonell N, Chazouilleres O, Poupon R. Hepatitis C virus induced hypobetalipoproteinemia: a possible mechanism for steatosis in chronic hepatitis C. J Hepatol 2001 34: 428 34.
26. Papatheodoridis GV, Chrysanthos N, Savvas S, et al. Diabetes mellitus in chronic hepatitis B and C: prevalence and potential association with the extent of liver fibrosis. J Viral Hepat 2006 13: 303 10.
27. Sanyal AJ, Contos MJ, Sterling RK, et al. Nonalcoholic fatty liver disease in patients with hepatitis C is associated with features of the metabolic syndrome. Am J Gastroenterol 2003 98: 2064 71.
28. Solis-Herruzo JA, Perez-Carreras M, Rivas E, et al. Factors associated with the presence of nonalcoholic steatohepatitis in patients with chronic hepatitis C. Am J Gastroenterol 2005 100: 1091 8.
29. Tsochatzis E, Papatheodoridis GV, Archimandritis AJ. The evolving role of leptin and adiponectin in chronic liver diseases. Am J Gastroenterol 2006 101: 2629 40.
30. Belfort R, Harrison SA, Brown K, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006 355: 2297 307.